FDA Approves Ortho-Prefest For Menopause Symptoms
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Ortho-Prefest For Menopause Symptoms

RARITAN, N.J. -- October 26, 1999 -- The U.S. Food and Drug Administration has approved Ortho-Prefest™ (17(beta)-estradiol/norgestimate) tablets, a new single tablet hormone replacement therapy (HRT) which combines 17(beta)-estradiol with the progestin, norgestimate. Ortho-Prefest is indicated in women with an intact uterus for the treatment of moderate to severe vasomotor symptoms associated with the menopause, treatment of vulvar and vaginal atrophy and prevention of osteoporosis.

During clinical trials of postmenopausal women, Ortho-Prefest was proven safe and effective in reducing hot flashes and providing relief from vaginal atrophy.

For women using Ortho-Prefest, the most commonly reported side effects during one year of treatment were headache (23 percent) and breast pain (16 percent). Most women did not find these side effects serious enough to discontinue therapy. Other side effects reported during clinical trials include, but are not limited to back pain, fatigue, flu-like symptoms, abdominal pain, nausea, arthralgias (joint pain), dysmenorrhea (painful menstruation), vaginal bleeding, vaginitis, pharyngitis (inflammation of the throat), sinusitis and URIs (upper respiratory infections).

Hormone replacement therapy is not suitable for all women. Women should talk to their healthcare professional before starting HRT.

Estrogens should not be used in women with known or suspected pregnancy, breast cancer, or estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; active thrombophlebitis; or thromboembolic disorders. Estrogens have been reported to increase the risk of serious side effects including thromboembolic disorders, cardiovascular disease and endometrial carcinoma in postmenopausal women. Progestins taken with estrogen drugs significantly reduce but do not eliminate the risk of endometrial cancer that is associated with the use of estrogen.

Ortho-Prefest will be manufactured by Ortho-McNeil Pharmaceutical. The date of product availability has not yet been determined.

Related Link: Ortho-McNeil Pharmaceutical.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities